Drugs News and Research

RSS

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

UC emergency medicine assistant professor compares efficacy of two seizure medications to prevent SE

When seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity. In a paper published in the June Academic Emergency Medicine, UC emergency medicine assistant professor Jason McMullan, MD, found that the best means of stopping status epilepticus may be with the least direct medication.

10 Jun 2010

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

10 Jun 2010

Copy number variants may cause autism: Study

An international consortium of researchers from more than 70 universities, including the University of Utah, has reported that a study of nearly 2,300 people supports the growing consensus that autism is caused in part by rare genetic changes called copy number variants (CNVs).

10 Jun 2010

MonoSol Rx, APR expand film formulation development collaboration

MonoSol Rx, the developer of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, and APR Applied Pharma Research s.a. ("APR") announced today an expansion of their relationship to identify and develop film formulations of prescription drug products beyond ondansetron and donepezil to include zolmitriptan. Zolmitriptan is currently commercially available for the acute treatment of migraine headache in adults, and facing initial patent expirations in 2012.

10 Jun 2010

Driving while distracted is equivalent to drunken driving

It's time for physicians to talk to patients about driving while distracted, a problem that has risen to the rough equivalence of drunken driving thanks to the proliferation of phones that allow drivers to talk and text, Amy Ship, MD, a primary care physician at Beth Israel Deaconess Medical Center suggests.

10 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

New findings may help researchers design drugs that can prevent HIV

Researchers at the University of Iowa Carver College of Medicine and University of Nebraska Medical Center have created a three-dimensional picture of an important protein that is involved in how HIV -- the virus responsible for AIDS -- is produced inside human cells. The picture may help researchers design drugs that can prevent HIV from reproducing.

10 Jun 2010

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal, explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

10 Jun 2010

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

10 Jun 2010

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.

10 Jun 2010

Fero Industries enters into Asset Acquisition Agreement with GVEST

Fero Industries, Inc. is pleased to announce that it has entered into an Asset Acquisition Agreement with GVEST Inc., an Ontario Corporation, for the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

10 Jun 2010

Autism is caused in part by CNVs: Study

10 Jun 2010

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Aestus Therapeutics, Inc. announced that it has been awarded a $2 million Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). The grant, from the NIH's National Institute of Neurological Disorders and Stroke (NINDS), will fund clinical trials of Aestus's novel, first-in-class treatment for chronic neuropathic pain.

9 Jun 2010

First clinical trial among African women to test vaginal ring that prevents HIV transmission

The nonprofit International Partnership for Microbicides today announced the initiation of the first trial among women in Africa testing a vaginal ring containing an antiretroviral drug that could one day be used to prevent HIV transmission during sex. The clinical trial, known as IPM 015, tests the safety and acceptability of an innovative approach that adapts a successful technology from the reproductive health field to give women around the world a tool to protect themselves from HIV infection.

9 Jun 2010

Enavail to build new cGMP facility in Abilene Life Sciences Accelerator

Enavail, LLC, a particle engineering company founded on pioneering drug delivery research from the University of Texas at Austin, announced today the company's plans for the construction of a new state-of-the-art current Good Manufacturing Practices (cGMP) facility in the Abilene Life Sciences Accelerator (ALSA). The Enavail facility will be the first of its kind in the West Texas region.

9 Jun 2010

Connections project to debate effectiveness of drug and alcohol interventions within criminal justice system

The second annual European gathering of the Connections project, a University of Kent-managed project co-funded by the European Commission Public Health Programme, will debate the ethics, effectiveness and economics of drug and alcohol interventions within the criminal justice system.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Drugs News and Research

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

UC emergency medicine assistant professor compares efficacy of two seizure medications to prevent SE

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Copy number variants may cause autism: Study

MonoSol Rx, APR expand film formulation development collaboration

Driving while distracted is equivalent to drunken driving

Mutations in ion channels cause rare inherited pain disorder: Research

New findings may help researchers design drugs that can prevent HIV

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Fero Industries enters into Asset Acquisition Agreement with GVEST

Autism is caused in part by CNVs: Study

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

First clinical trial among African women to test vaginal ring that prevents HIV transmission

Enavail to build new cGMP facility in Abilene Life Sciences Accelerator

Connections project to debate effectiveness of drug and alcohol interventions within criminal justice system

Some commonly used drugs cause bone loss: New research

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News